In prostate cancer, high level of IGFBP-1 was associated with increased cancer risk and a shorter time to castration resistant prostate cancer from androgen deprivation therapy (ADT) and reduced OS (141, 142). This evidence concerns the gene IGFBP1 and prostate cancer.